Kihara James 4

What Happened

• Kihara James, Principal Accounting Officer of ACADIA Pharmaceuticals (ACAD), received equity awards on March 6, 2026. The filing shows two grants: 21,766 derivative securities (stock options) and 6,332 restricted stock units (RSUs). Both awards were granted at $0.00 (award/grant), so no cash was paid.
• Total awarded: 28,098 securities (21,766 options + 6,332 RSUs). These are compensation awards rather than open-market purchases or sales.

Key Details

• Transaction date: March 6, 2026; Filing date: March 10, 2026 (timely filing).
• Grant price: $0.00 (award/grant).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1 (applies to the 21,766 options): 25% of the options vest on March 6, 2027; remaining options vest in 36 equal monthly installments thereafter.
  • F2 (applies to the RSUs): Each RSU represents a contingent right to one share of common stock.
  • F3 (applies to the RSUs): RSUs vest in four equal annual installments beginning March 6, 2027.
• Transaction code A = Award/Grant (not a purchase or sale).

Context

• These are grants for future compensation. The options require vesting before exercise; the RSUs convert to shares only as they vest. Neither award represents an immediate sale or purchase of shares on the open market.
• Such grants are common as part of executive compensation and do not by themselves indicate insider buying or selling intent. Monitor vesting dates for when shares may become issuable or exercisable.